The evaluation effects of the Livercare tablet (combination of Milk Thistle, Dandelion, Barberry, Tumeric (Curcumin) and Artichoke) in the prevention of anti-tuberculosis drugs-induced hepatotoxicity
Phase 2
Recruiting
- Conditions
- Tuberculosis.Respiratory tuberculosis
- Registration Number
- IRCT20171230038142N16
- Lead Sponsor
- Esfahan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 44
Inclusion Criteria
Age range 20 to 65
Active pulmonary or extrapulmonary tuberculosis
No first-line anti-tuberculosis drugs (isoniazid, rifampin, pyrazinamide) in all patients in the past 8 weeks and starting on treatment
No known hepatotoxic drugs (sodium valproate, methotrexate and sulfonamides)
No continuous use of acetaminophen
No systemic glucocorticoids, supplements containing thistle, dandelion, barberry, turmeric or artichoke in the past 4 weeks
Exclusion Criteria
Patient dissatisfaction
alcohol consumption
liver disease
Discontinue medication for any reason other than liver toxicity
Patient Withdrawal from Study Continuation
Not taking the study tablet for at least 3 consecutive days
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Hepatic Enzymes (AST, ALT, ALP). Timepoint: Before and one week and two weeks after intervention. Method of measurement: blood test.;Bilirubin (Direct and Total). Timepoint: Before and one week and two weeks after intervention. Method of measurement: blood test.
- Secondary Outcome Measures
Name Time Method